← Back to Search

Light Exposure and Sleep Scheduling for Teen Sleep Disorders

N/A
Waitlist Available
Led By Brant P Hasler, PhD
Research Sponsored by University of Pittsburgh
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Currently in 11th or 12th grade and enrolled in a traditional high-school; or cyber school with synchronous classes (not home-schooled)
Age 16-19 years
Timeline
Screening 3 weeks
Treatment Varies
Follow Up during follow-ups after the manipulation through study completion, up to 5 years
Awards & highlights

Study Summary

This trial will study whether sleep disorders in adolescence are linked to an increased risk of substance abuse, and whether treatment can help.

Who is the study for?
This study is for teens aged 16-19, in their junior or senior year of high school (traditional or cyber but not home-schooled), who are physically and mentally healthy. Participants must have a late sleep schedule with weekend bedtimes at 1 AM or later, and can't be using drugs other than alcohol, cannabis, and nicotine.Check my eligibility
What is being tested?
The trial tests if increasing morning light exposure, reducing evening blue light exposure, monitoring sleep patterns along with mood and substance use, and regulating sleep schedules can reduce the risk of substance abuse linked to delayed sleep phase in adolescents.See study design
What are the potential side effects?
There may be minimal side effects from this behavioral intervention. However, changes in light exposure could potentially affect mood temporarily or disrupt usual sleeping patterns during the adjustment period.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a high school junior or senior in a traditional or online school with live classes.
Select...
I am between 16 and 19 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~during follow-ups after the manipulation through study completion, up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and during follow-ups after the manipulation through study completion, up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Behavioral inhibition
Circadian alignment
Neural correlates of impulse control
+2 more
Secondary outcome measures
Cannabis use

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: ManipulationExperimental Treatment4 Interventions
For ~2 weeks, participants will be asked to adhere to the following: Sleep scheduling--advance bedtime by 1.5 hours ( + sleep duration) Decrease evening blue light exposure via blue blocker goggles (2 h before bed) Increase morning bright light exposure via bright light goggles (30 m after rise) Monitor sleep, mood, and substance use via smartphone-based platform and wrist actigraph
Group II: ControlActive Control1 Intervention
For ~2 weeks, participants will asked to adhere to the following: - Monitor sleep, mood, and substance use via smartphone-based platform and wrist actigraph
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Sleep scheduling
2009
Completed Phase 2
~70

Find a Location

Who is running the clinical trial?

University of PittsburghLead Sponsor
1,731 Previous Clinical Trials
16,307,285 Total Patients Enrolled
1 Trials studying Delayed Sleep Phase Syndrome
100 Patients Enrolled for Delayed Sleep Phase Syndrome
National Institute on Drug Abuse (NIDA)NIH
2,488 Previous Clinical Trials
2,622,504 Total Patients Enrolled
1 Trials studying Delayed Sleep Phase Syndrome
100 Patients Enrolled for Delayed Sleep Phase Syndrome
Brant P Hasler, PhDPrincipal InvestigatorUniversity of Pittsburgh

Media Library

Monitor sleep, mood, and substance use Clinical Trial Eligibility Overview. Trial Name: NCT03806296 — N/A
Delayed Sleep Phase Syndrome Research Study Groups: Control, Manipulation
Delayed Sleep Phase Syndrome Clinical Trial 2023: Monitor sleep, mood, and substance use Highlights & Side Effects. Trial Name: NCT03806296 — N/A
Monitor sleep, mood, and substance use 2023 Treatment Timeline for Medical Study. Trial Name: NCT03806296 — N/A
~23 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top